Lukang Pharmaceutical announced that the company recently received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for lenvatinib mesylate issued by the State Drug Administration. The drug approved the marketing application. As of the announcement date, the company has invested a total of about 5.73 million yuan in research and development of this drug.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.